DS
KYNB

David Shaw’s Kyntra Bio KYNB Stock Holding History

David Shaw’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-400
Closed -$405K – 3938
2020
Q2 		$405K Buy
+400
New +$371K ﹤0.01% 3492

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
GC
GFG Capital Miami, Florida $363M AUM 45.53% 1-Year Est. Return

David Shaw's KYNB Position: Q3 2024 in Review

David Shaw sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 407 shares — an estimated $9.09K sold.

David Shaw first reported a position in KYNB in Q4 2014 and held it in 26 quarters. The position peaked at $7.58M in Q4 2018. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.

  • David Shaw reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
  • David Shaw sold 407 Kyntra Bio shares in Q3 2024, an estimated $9.09K.
  • David Shaw first reported a position in Kyntra Bio in Q4 2014 and held it in 26 quarters.
  • David Shaw's Kyntra Bio position peaked at $7.58M in Q4 2018.
  • 70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.